Pharmaceutical stalwart Adcock Ingram should provide an investment portfolio with some immunity to any market malaise. The group certainly has some healthy attributes.
A 3% dip is the worst annual performance Adcock has posted in headline earnings per share (HEPS) over the past decade, and it came during the Covid-infected year of 2021. Most years have been far stronger, highlighting the company’s resilience and tight operational control. Since 2015, Adcock has delivered an impressive 16.2% compound annual growth rate in HEPS. Sector heavyweight Aspen Pharmacare managed just 1.85% over the same period.
Given this track record, you might expect Adcock’s shares to trade at a premium. They don’t. The stock carries a trailing p:e multiple of just 7.9 — a bargain by almost any standard. Aspen, despite a bruising recent sell-off after losing a major contract and carrying a much heavier net debt-to-earnings before interest, tax, depreciation and amortisation (ebitda) ratio of three, still trades at 8.86. On paper, the gap looks strange: stronger earnings growth, lower leverage — with Adcock’s net debt-to-ebitda ratio sitting comfortably at 0.5 — and a business model that has proved resilient over time. So what side effects are worrying the market?
The answer probably lies in the geography of profits. Aspen earns only about 25% of its pharmaceutical division profits from South Africa, giving it valuable international diversification — and, critically, insulation from rand volatility. Adcock, by contrast, remains overwhelmingly South African, apart from an Indian joint venture that contributes about 15% of earnings.
This concentration carries real risks. Adcock not only fails to offer investors a rand hedge; it actively suffers when the currency weakens. Heavily reliant on imported active pharmaceutical ingredients and finished goods, Adcock sees its input costs rise sharply when the rand falls, squeezing margins in a way that dollar-based businesses are largely able to avoid.
Charles Boles, founder of Titanium Capital, points out that in the three years from 2009 to 2011 Adcock’s gross profit margin held between 49% and 53%, with the operating margin sitting at about 24%-27%. In the past financial year the group’s gross profit margin had been whittled down to 32.4%, with the operating profit margin dissolving to 12.8%. “That’s a significant deterioration. In 2010 the return on equity at Adcock was 29%, compared with about 14%-15% now.”
Compounding the problem is South Africa’s single exit price (SEP) system, which regulates the prices of prescription medicines and certain hospital products in the private sector. Introduced to promote fairness and transparency in drug pricing, SEP allows pharmaceutical companies only one government-approved price increase a year — often below inflation and input cost rises. Over-the-counter (OTC) products are largely exempt, but with nearly 60% of Adcock’s turnover falling under SEP, the constraint is significant. Combined with the fact that 58% of its pharmaceutical products are sourced from third parties, the problem is clear: Adcock faces rising import costs driven by a weaker rand and health-care inflation, but has limited ability to pass them on to consumers.
By contrast, Aspen’s footprint in Asia, Europe, Latin America, North America and Australia places it in markets where price controls are either less stringent or differently structured. While many countries regulate drug prices in some form, few apply a system as blunt as South Africa’s SEP. For example, in Europe and parts of Asia, reference pricing and negotiated tender systems dominate, allowing for more dynamic price adjustments. In the US, pricing is also more market-driven, albeit politically sensitive.
Boles notes that 15 years ago Adcock’s prescription and hospital segments had operating margins of 32% and 19% respectively; now these are only 10% and 6%. “These have been the key pain points for Adcock under the SEP mechanism.”
Another factor buoying Aspen’s relative valuation is its aspirational growth narrative. Aspen has invested heavily in expanding its sterile manufacturing capacity, particularly for high-margin injectable products. The thesis is that surplus manufacturing capacity — built up at considerable cost — will eventually be filled with new contracts and new product lines, driving operating leverage and margin expansion. The realisation of this vision has been patchy at best, but the possibility of future upside remains a powerful magnet for investors looking for growth stories in a slow-growing economy.
By contrast, Adcock’s growth drivers appear limited. The company continues to perform well operationally, but its future seems anchored to incremental expansion within the mature South African market, with limited new product rollouts and modest opportunities for geographic diversification. Without a compelling new growth leg, it is difficult for investors to assign a higher earnings multiple, regardless of the company’s strong historical performance.
Adcock Ingram’s operations today span four major divisions: prescription, OTC, hospital and consumer. Prescription, OTC and hospital products are sold primarily through pharmacies and hospitals, while the consumer division — home to health care, personal care and home-care brands — targets retail store shelves. Together, these businesses form the backbone of the company’s resilience. Though financial results for the interim 2025 period came in below management’s expectations, Adcock’s operational depth and underlying strength were evident.
“We concede that the financial performance for the reporting period ended well below expectations,” CEO Andy Hall admitted frankly during the results webcast. Turnover decreased by 1% to R4.7bn, pressured by lower volumes in the independent wholesale channel that services lower-LSM retail consumers, and a cautious restocking approach from major pharmaceutical wholesalers.
“We saw three of our larger pharmaceutical wholesalers reducing their inventory holdings over the period, particularly from October onwards,” Hall said. This dynamic masked some underlying market strength, with IQVIA data showing Adcock still growing 4% in the total private sector over the past year, maintaining its place as the No 1 pharmaceutical player in South Africa.
Adcock’s manufacturing capabilities are central to its value chain, but capacity underutilisation weighed heavily on profitability. “The biggest culprit was significantly reduced production levels, particularly at our Wadeville plant,” Hall said, noting that the factory — servicing the prescription and OTC divisions — operated far below optimal levels, hammering gross margins and halving the prescription division’s trading profit.
The problem traces back to the government’s HIV antiretroviral (ARV) tender programme. Adcock, unable to match the ultra-low pricing offered by Indian manufacturers, deliberately scaled back its participation in recent tenders, exiting a market segment where margins had become unsustainably thin. As a result, Wadeville, once a major producer of oral solid dosage forms for ARV contracts, is now largely reliant on smaller, non-ARV tablet runs and low-volume batches of oral liquids and syrups. Water supply interruptions in Gauteng have compounded the strain, further disrupting production and worsening the underutilisation.
Despite these setbacks, some divisions eked out positive momentum. In OTC, Adcock remains a dominant force in pharmacy channels, leading key categories such as pain, cold and flu and digestive products. “Our OTC division has maintained its share over the period of almost 20%, according to IQVIA,” Hall said. Though revenue dipped 4%, mainly due to destocking from wholesalers affecting brands such as Corenza C, Alcophyllex and Adco-Linctopent, the pain portfolio held steady with solid growth from products including Adco-Dol and Mypaid. Trading profit in OTC actually improved by 4% to R172m, a testament to tight cost control and steady front-shop sales at pharmacies.
The consumer division had a tougher ride. Brands such as Panado, Bioplus, and Compral — usually strong sellers in the independent wholesale market — saw weaker demand, driven by stressed lower-income consumers. Hall said: “We saw sales of our premium brands in the independent wholesale channel being weak.” He attributed this to economic pressure and shifting purchasing behaviour towards smaller, more affordable pack sizes.
Yet there were bright spots too. Pharmacy and fast-moving consumer goods channel sales grew, and newer brands such as Epi-Max, GynaGuard, Island Tribe and Plush posted double-digit revenue gains. Dermopal, a sunscreen brand acquired in mid-2024, also added more than R30m to revenue during the period.
The Clayville manufacturing facility, which produces high-volume oral liquids or syrups and effervescents, powders and eye drops, supported this side of the business. “From an overall perspective, we were happy with the operational performance of the Clayville factory,” Hall said, even though minor throughput declines occurred due to regulatory audits.
The prescription division, covering branded and generic medicines, as well as specialist goods such as skincare products and ophthalmology devices, struggled. Revenue dropped 5%, again largely due to wholesale destocking and Adcock’s strategic pullback from the low-margin ARV tender market. “Our ARV revenue is less than R40m, less than 1% of our total sales,” Hall said. He emphasised that private sector ARV sales would continue where margins were viable, but that public sector sales now accounted for only 9% of total group turnover.
Looking ahead, Hall expressed cautious optimism for volume recovery. “I certainly think in all three of the pharmaceutical divisions — consumer, OTC and prescription — we will see better volumes than what we saw in half one,” he said, though he warned that broader market volumes were still negative according to December IQVIA data. He said strategic moves into the informal sector for Panado, Compral and Bioplus could aid recovery, and winter, being flu season, could boost OTC volumes.
Adcock’s hospital division was one of the few clear bright spots. Turnover rose 10%, driven by a 12% surge in the medicine delivery portfolio, which houses the group’s intravenous fluids, following a major win in October 2023 when Adcock secured 90% of a key three-year large-volume parenterals (LVP) public sector tender. Renal products also posted solid low-double-digit growth.
“The Aeroton facility where we produce the intravenous products continues to run at full capacity,” Hall said. Even so, ageing infrastructure remains a challenge. While the group is investing in projects to maintain compliance and protect output quality, management has cautioned that large-scale capital expenditure is unlikely. Without firm guarantees of sustained demand, the risks of major upgrades are simply too high.
Gross margin pressures continued to show up across the business due to mix effects — higher LVP sales have lower margins — and the loss of high-margin speciality blood products. Still, trading profit in the hospital division held steady, reflecting strong operational execution. New partnerships with global players such as Convatec and Medline are expanding Adcock’s wound care and hospital consumables offering, further diversifying revenue streams.
CFO Dorette Neethling highlighted that while trading profit dropped by 17% group-wide to R515m, the decline in HEPS was contained to 9% thanks to strong performances from joint ventures and share buybacks. “At the operating expense level, our teams did a good job. Expenses increased by only 3%, below inflation,” she said, showcasing management’s operational discipline despite revenue headwinds.
The company’s manufacturing review could yield long-term margin benefits. “We’re busy with a strategic review of all our manufacturing facilities,” Hall said, adding that better allocation between South Africa and offshore partners, particularly in India, could lower costs. “But you can’t make everything in India,” he noted, “so it does make sense to keep a portion of our production here in South Africa.”
Despite the tough interim performance, Hall remained pragmatic about the outlook. “I’m more positive for H2,” he said, citing early signs of volume recovery and internal initiatives to reignite momentum.
The proposed rollout of National Health Insurance (NHI) could be a double-edged sword for Adcock. On one hand, expanded health-care access for millions of South Africans could significantly boost demand for basic medicines, hospital products and vaccines. Adcock’s strong footprint in private and public sector supply chains means it is well positioned to capture new volumes.
Hall has consistently emphasised the group’s role as a local manufacturer and reliable supplier, noting that more than 90% of South Africa’s life-saving large-volume intravenous fluids for the public sector, and more than 60% for the private sector, are produced at Adcock’s Aeroton facility. That embedded market share, especially in critical care, would be difficult for new entrants to replicate under an NHI regime.
On the other hand, NHI also raises the spectre of even tighter pricing controls and squeezed margins, in a pharmaceutical sector already constrained by the SEP system. Increased government procurement under NHI could lead to larger tenders but at razor-thin margins, forcing Adcock to rely even more heavily on scale and operational efficiency to protect profitability.
International factors also complicate the medium-term picture. The pharmaceutical tariffs imposed by the US on imports from China and India have disrupted global supply chains and could have ripple effects for Adcock’s operations, especially the group’s manufacturing joint venture in India. For now, Adcock’s exposure is limited, since most of its Indian production serves the local South African market rather than the US. However, any escalation of global pharmaceutical tariffs could indirectly inflate input costs, given that many raw materials originate from Asia.
Conversely, rising global costs for pharma supply could make locally produced, rand-denominated products more competitive against imports, a dynamic that would favour Adcock’s manufacturing footprint in Wadeville, Clayville and Aeroton.
One area that investors increasingly scrutinise is exposure to next-generation therapeutics, particularly the exploding GLP-1 segment for diabetes and weight loss. Companies such as Novo Nordisk and Eli Lilly have rerated dramatically on the back of surging demand for drugs such as Ozempic and Mounjaro. For now, Adcock has no direct exposure to GLP-1 products.
Nonetheless, Adcock’s history of partnering with multinationals for distribution agreements could leave the door open for selective participation if GLP-1 therapies become more accessible. Hall recently highlighted that Adcock is linking up with new multinational partners and expanding its relationship with Lundbeck; there’s also a pending collaboration with GSK on vaccines.
“We continue to engage with a number of multinational companies to add their products to our basket so we can perform their marketing, sales and distribution activities in South Africa,” he said, suggesting that strategic distribution partnerships could offer a low-risk way to participate in GLP-1 trends without heavy investment.
Anchor Capital equity analyst Sean Culverwell is more sceptical, arguing that Adcock won’t be able to access Eli Lilly’s portfolio given that company’s tie-up with Aspen, and Novo Nordisk appears to be selling directly to the wholesalers. However, he concedes there may be a window of opportunity in the future. “Semaglutide — the base molecule in Wegovy and Ozempic — is coming off patent in several emerging markets this year. This could allow Adcock to explore partnerships with Indian generic manufacturers down the line. For now, though, the current wave is likely out of reach. “
With Adcock’s stock trading this cheaply — the market disfavouring companies that lack a clear growth narrative — the most logical move has been to prioritise share buybacks over expansion. This is a strategy the company has executed effectively over the past three years.
Investors could do worse than to follow that lead. Operating in a defensive sector and offering a healthy 5% dividend yield that rewards patience, Adcock remains well positioned. And with Bidvest already holding a controlling stake, the possibility of a buyout offer to minorities remains a possibility.
Adcock Ingram arguably suffers from investor concerns about its size and market perception. Aspen Pharmacare, as the larger and more internationally recognised player, has greater liquidity in its shares and is seen as more of an institutional stock, which naturally commands a slight premium. In addition, Aspen’s strategic repositioning towards complex manufacturing and away from commoditised products — though it is still a work in progress — is perceived as positioning the company for better long-term profitability, even if the current execution has been uneven.
Of course, of the two, Adcock boasts the far longer history. Founded in 1891 as a modest pharmacy in Krugersdorp, it grew steadily into one of South Africa’s leading pharmaceutical players, producing branded and generic medicines, over-the-counter products and hospital and critical-care solutions for the private and public sectors.
Its first major milestone came in 1950, with a listing on the JSE. It quickly earned blue-chip status and became a fixture of the country’s industrial landscape. In 2000 majority shareholder Tiger Brands bought out the remaining minorities, took Adcock private and folded it into its consumer goods empire. For a few years Adcock operated inside Tiger’s sprawling conglomerate, but the promised synergies never fully materialised.
In 2008 Adcock Ingram was relisted as an independent company when Tiger Brands unbundled it to shareholders, allowing the business to refocus on its pharmaceutical roots. The group wasted little time in flaunting its newfound freedom, pitching a takeover bid for smaller rival Cipla Medpro in 2009. The bid was withdrawn, though in the next few years Adcock bolted on several smaller businesses.
But independence from Tiger Brands brought its own turbulence. In 2013 a fierce battle for control erupted between local powerhouse Bidvest Group and Chilean multinational CFR Pharmaceuticals. After months of boardroom drama, Bidvest ultimately gained the upper hand, stabilising Adcock’s ownership and restoring operational focus.
That battle for control of Adcock, interestingly, was waged at markedly higher share prices. Bidvest initially pitched a R65 a share offer, and later CFR emerged with a bid that ranged between R73.51 and R75 a share. CFR’s offer was worth $1.6bn — then equivalent to R12.6bn — compared with Adcock Ingram’s market value of just under R8bn today.
It might be worth recalling that the Adcock tie-up with CFR was envisaged to create a formidable emerging-markets pharmaceuticals company with listings in Santiago and Joburg, targeting a market of more than 2-billion patients across Latin America, Africa, Southeast Asia and India.
Bidvest, notwithstanding an increased offer price from CFR, eventually won out in 2014. In April that year Adcock CEO Jonathan Louw unsurprisingly stepped down.
The role of Bidvest also shapes the investment case. It is Adcock’s largest shareholder, with a 64.8% stake, but the conglomerate’s strategic intentions remain a point of debate. For now, Bidvest appears content to treat Adcock as a stable, cash-generative investment rather than as a platform for aggressive expansion. Adcock’s disciplined dividend policy and cautious acquisition strategy mirror Bidvest’s broader focus on cash flow and capital return. In response to investor questions at the February 2025 results presentation, Adcock CEO Andy Hall confirmed that “there’s nothing on the table” in terms of major acquisitions, underscoring a measured, organic growth approach.
Bidvest’s deep operational resources and appetite for bolt-on acquisitions could become far more relevant if market conditions improve or if Adcock identifies attractive assets outside the price-regulated space, such as personal care, pharmacy front-shop products or adjacent consumer health-care categories. In an environment of rising regulatory pressure and shrinking margins, scale could become a decisive advantage — and Bidvest’s patient capital and strategic firepower would be an obvious asset if consolidation opportunities emerge.
Urquhart Partners founder Richard Cheesman believes Adcock has been somewhat constrained under Bidvest’s ownership, given that the parent company is not a pharma specialist. “Bidvest typically prefers full ownership of its subsidiaries and tends to avoid having listed entities in the group, which makes Adcock something of an outlier. The path forward is unclear, but a few scenarios, such as a buyout of minority shareholders, a joint venture with an international pharma player or even a sale of the business, would all be strategically logical.”
Rowan Williams, chief investment officer at Nitrogen Fund Managers, agrees that Bidvest is a neutral holder of Adcock, and would consider selling its stake if it got a compelling offer. But given Adcock’s exposure to the health-care space, Williams does not believe that Bidvest would consider buying out minorities and delisting the company, as it does not fit easily into the broader Bidvest portfolio and focus on business services.
Sean Culverwell, equity analyst at Anchor Capital, points out that Bidvest remains adamant that it will not pay a premium for Adcock. “Adcock is a nice strategic [asset] for Bidvest’s portfolio, given its defensive earnings base, and it diversifies Bidvest’s local earnings stream,” he says. “It seems Bidvest’s capital allocation priority is to bulk up its offshore services footprint with a view to listing that business separately — like it did Bidcorp. I expect any discretionary capital will be directed there in the medium term. I don’t expect Bidvest to deploy the R3bn or more required to buy out minority shareholders in the near term.”
Culverwell says that if an offshore suitor puts forward an offer, Bidvest will consider it in the context of its current portfolio restructuring. “However, until then, Adcock remains a reliable source of cash.”
Cheesman highlights the presence of India-based Natco Pharma on the Adcock share register. “Natco Pharma may hold only a small stake in Adcock, but with a strong cash position and global ambitions, it’s not a player to dismiss outright. For now, we watch with interest to see what unfolds.”
Culverwell agrees that Natco Pharma’s presence on the share register is intriguing, especially as Hall has confirmed there is no commercial relationship between the companies. “However, given Natco’s current struggles — including a 42% drop in share price following revenue declines — I don’t see its involvement leading to any material developments in the short term.”
Williams, though, reckons Natco Pharma’s small shareholding does seem to indicate that there are potential foreign buyers of Adcock, as Natco will also realise that Bidvest may consider disposing of its holding. “If we see an uptick in growth in South Africa, then Adcock will become a more attractive takeover target for an international player looking to gain exposure to the South African market.”
Titanium Capital founder Charles Boles says Adcock needs to focus on growing its non-single exit price (SEP) business, with 59% of the group’s operations still subject to that margin-limiting arrangement. “With a government determined to reduce the cost of health care, you are on the wrong side of the river if you are predominantly plying your trade in the SEP categories.”
Boles points out that Adcock’s overseas peers have in many instances spun out their consumer health businesses, like Johnson & Johnson did with Kenvue in mid-2023 and GSK did with Haleon a year earlier. “When pharma companies spin off their consumer health arms, these businesses get rosy ratings — sometimes between 25 and 30 times earnings.”
Boles says the problem for Adcock is that its market rating is about eight or nine times earnings, and to grow its consumer health business it will have to make acquisitions. “Very seldom do quality branded businesses come onto market … and if they do, they don’t come with price tags of eight or nine times earnings. As much as Adcock might want to grow, there aren’t many great investment opportunities around at the moment.”
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.